Journal Mobile Options
Table of Contents
Vol. 98, No. 2, 2013
Issue release date: October 2013
Section title: Original Paper
Neuroendocrinology 2013;98:156-168
(DOI:10.1159/000355152)

Prognostic Factors and Long-Term Outcome of Pancreatic Neuroendocrine Neoplasms: Ki-67 Index Shows a Greater Impact on Survival than Disease Stage. The Large Experience of the Spanish National Tumor Registry (RGETNE)

Martin-Perez E. · Capdevila J. · Castellano D. · Jimenez-Fonseca P. · Salazar R. · Beguiristain-Gomez A. · Alonso-Orduña V. · Martinez del Prado P. · Villabona-Artero C. · Diaz-Perez J.A. · Monleon A. · Marazuela M. · Pachon V. · Sastre-Valera J. · Sevilla I. · Castaño A. · Garcia-Carbonero R.
Departments of aSurgery, University Hospital La Princesa, Madrid, bMedical Oncology, University Hospital Vall d'Hebron, Barcelona, cMedical Oncology, University Hospital 12 de Octubre, Madrid, dMedical Oncology, Hospital Central de Asturias, Oviedo, eMedical Oncology, Hospital Duran i Reynals, Institut Catalá d'Oncologia, Barcelona, fSurgery, Hospital de Donostia, San Sebastian, gMedical Oncology, Hospital Miguel Servet, Zaragoza, hMedical Oncology, Hospital de Basurto, Vizcaya, iEndocrinology, Hospital de Bellvitge, Barcelona, jEndocrinology, University Hospital Clinico San Carlos, Madrid, kStatistics, Faculty of Biology, Barcelona University, Barcelona, lEndocrinology, University Hospital La Princesa, Madrid, mMedical Oncology, Hospital Ramon y Cajal, Madrid, nMedical Oncology, University Hospital Clinico San Carlos, Madrid, oMedical Oncology, Hospital Virgen de la Victoria, Malaga, pPathology, University Hospital Fuenlabrada, Madrid, and qMedical Oncology, University Hospital Virgen del Rocio, Institute de Biomedicina de Sevilla (IBIS), HUVR, CSIC, Universidad de Sevilla, Sevilla, Spain

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 2/25/2013
Accepted: 8/21/2013
Published online: 9/19/2013

Number of Print Pages: 13
Number of Figures: 2
Number of Tables: 6

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN

Abstract

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are uncommon neoplasms with a wide spectrum of clinical behavior. The objective of this study was to assess in a large cohort of patients the relative impact of prognostic factors on survival. Methods: From June 2001 through October 2010, 1,271 patients were prospectively registered online (www.getne.org) at the Spanish National Cancer Registry for Gastroenteropancreatic Neuroendocrine Tumors (RGETNE) by participating centers. Clinical and histopathological features were assessed as potential prognostic factors by uni- and multivariate analyses. Results: Of 483 PNENs, 171 (35%) were functional (F) and 312 (65%) non-functional (NF). NF-PNENs were associated with a higher incidence of histological features denoting more aggressive disease, such as poor tumor differentiation, Ki-67 >20%, or vascular invasion (NF- vs. F-PNENs, respectively, p < 0.05). Nevertheless, functionality was not a significant predictor of survival (p = 0.19). Stage at diagnosis, Ki-67 index, tumor differentiation and surgical resection of the primary tumor were all significant prognostic factors in univariate analysis. However, Ki-67 (>20 vs. ≤2%) (hazard ratio (HR) 2.21, p = 0.01) and surgical resection (yes vs. no) (HR 0.92, p = 0.001) were the only independent predictors of survival in multivariate analysis. Among patients who underwent surgery, high Ki-67 index (HR 10.37, p = 0.02) and poor differentiation (HR 8.16, p = 0.03) were the only independent predictors of clinical outcome. Conclusion: Ki-67 index and tumor differentiation are key prognostic factors influencing survival of patients with PNENs and, in contrast to what it is observed for other solid malignancies, they seem to have a greater impact on survival than the extent of disease. This should be borne in mind by physicians in order to appropriately tailor therapeutic strategies and surveillance of these patients.


  

Author Contacts

Dr. R. Garcia-Carbonero
Department of Medical Oncology, Hospital Universitario Virgen del Rocio
Instituto de Biomedicina de Sevilla (IBIS), HUVR, CSIC, Universidad de Sevilla
Avenida Manuel Siurot, s/n, ES-41013 Seville (Spain)
E-Mail rgcarbonero@gmail.com

  

Article Information

Received: February 25, 2013
Accepted after revision: August 21, 2013
Published online: September 19, 2013
Number of Print Pages : 13
Number of Figures : 2, Number of Tables : 6, Number of References : 44
Additional supplementary material is available online - Number of Parts : 2

  

Publication Details

Neuroendocrinology (International Journal for Basic and Clinical Studies on Neuroendocrine Relationships)

Vol. 98, No. 2, Year 2013 (Cover Date: October 2013)

Journal Editor: Millar R.P. (Edinburgh)
ISSN: 0028-3835 (Print), eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 2/25/2013
Accepted: 8/21/2013
Published online: 9/19/2013

Number of Print Pages: 13
Number of Figures: 2
Number of Tables: 6

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.